INVIVYD INC (IVVD) Stock Price, Quote, News and Summary
NASDAQ:IVVD - Nasdaq - US00534A1025 - Common Stock
IVVD Quote and Key Statistics
INVIVYD INC
NASDAQ:IVVD (1/17/2025, 8:09:09 PM)
After market: 0.429 +0.02 (+5.56%)0.4064
-0.03 (-7.49%)
IVVD Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -139.04% | ||
| ROE | -270.72% | ||
| Debt/Equity | 0 |
IVVD Performance and Technical Analysis
IVVD Ownership and Analysts
IVVD Latest News and Analysis
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on stock movements.
Get insights into the top gainers and losers of Friday's pre-market session.
What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?
On Friday, Invivyd Inc. (NASDAQ:IVVD) announced that new in vitro neutralization data show continued neutralizing activity of Pemgarda (pemivibart) and pipeline candidate VYD2311 against dominant SARS-CoV-2 variant XEC. The stock is trading with a strong session volume of 12.3 million, compared to an average volume of 757.02k as per data from Benzinga Pro. As anticipated, the data are largely consistent with those previously reported for KP.3.1.1, based on the structural biology of pemivibart an
What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?
Invivyd's new data highlights Pemgarda's activity against SARS-CoV-2 XEC and over 75% of variants, with consistent neutralization since Omicron BA.1.
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC
New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against XEC Centers for Disease Control reports...
About IVVD
Company Profile
Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is headquartered in Waltham, Massachusetts and currently employs 94 full-time employees. The company went IPO on 2021-08-06. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The firm delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2 (COVID-19). Its PEMGARDA is the Company’s first mAb in a planned series of innovative mAb candidates designed to keep pace with SARS-CoV-2 viral evolution. Its VYD2311 is optimized for neutralization potency against recent SARS-CoV-2 lineages such as BA.2.86 and JN.1. The firm also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.
Company Info
INVIVYD INC
1601 Trapelo Road, Suite 178
Waltham MASSACHUSETTS US
Employees: 95
Company Website: https://invivyd.com/
Investor Relations: https://investors.invivyd.com/
Phone: 17818190080
IVVD Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.96 | 303.17B | ||
| AMGN | AMGEN INC | 14.16 | 146.27B | ||
| GILD | GILEAD SCIENCES INC | 20.73 | 114.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 827.45 | 108.68B | ||
| REGN | REGENERON PHARMACEUTICALS | 15 | 74.90B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.30B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.76B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.97B | ||
| ONC | BEIGENE LTD-ADR | N/A | 22.37B | ||
| NTRA | NATERA INC | N/A | 20.91B | ||
| BIIB | BIOGEN INC | 8.61 | 20.48B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.76 | 16.02B |